Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.
作者： Ruth M. Ruprecht
DOI: 10.1007/978-1-59745-554-1_31
关键词: Human immunodeficiency virus (HIV) 、 Acquired immunodeficiency syndrome (AIDS) 、 Immunization 、 Monoclonal antibody 、 Virology 、 Biology 、 Antibody 、 Macaque 、 Immunodeficiency 、 Simian immunodeficiency virus
摘要: After more than 20 years of intense research, a safe and effective vaccine against HIV-1/AIDS has not been developed. Passive immunization used as tool to demonstrate the role neutralizing antibodies in conferring protection HIV-1 challenge chimpanzees. Because these animals are endangered studies difficult conduct with this species, chimeric viruses, termed simian-human immunodeficiency viruses (SHIVs), have generated that encode envelope gene backbone simian virus (SIV). SHIVs replicate several macaque species can induce AIDS animals. human monoclonal (nmAbs) protected rhesus macaques from SHIV infection provided proof-of-concept protective effects antibodies. At same time, nmAbs be evaluated for safety efficacy SHIV/macaque model therapeutic modalities their own right prevention, post-exposure prophylaxis, or possibly use. Experimental details testing infant monkeys, which allows without need generate large amounts nmAbs.
springer.com
sci-hub.se 参考文章(7)
Timothy W. Baba, Vladimir Liska, Regina Hofmann-Lehmann, Josef Vlasak, Weidong Xu, Seyoum Ayehunie, Lisa A. Cavacini, Marshall R. Posner, Hermann Katinger, Gabriela Stiegler, Bruce J. Bernacky, Tahir A. Rizvi, Russell Schmidt, Lori R. Hill, Michale E. Keeling, Yichen Lu, Joel E. Wright, Ting-Chao Chou, Ruth M. Ruprecht, Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection Nature Medicine. ,vol. 6, pp. 200- 206 ,(2000) , 10.1038/72309
Victor G Kramer, Nagadenahalli B Siddappa, Ruth M Ruprecht, None, Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes Current HIV Research. ,vol. 5, pp. 642- 655 ,(2007) , 10.2174/157016207782418506
C. Mc Cann, R. Song, R. Ruprecht, Antibodies: Can They Protect Against HIV Infection? Current Drug Targets - Infectious Disorders. ,vol. 5, pp. 95- 111 ,(2005) , 10.2174/1568005054201580
Flavia Ferrantelli, Robert A. Rasmussen, Kathleen A. Buckley, Pei‐Lin Li, Tao Wang, David C. Montefiori, Hermann Katinger, Gabriela Stiegler, Daniel C. Anderson, Harold M. McClure, Ruth M. Ruprecht, Complete Protection of Neonatal Rhesus Macaques against Oral Exposure to Pathogenic Simian-Human Immunodeficiency Virus by Human Anti-HIV Monoclonal Antibodies The Journal of Infectious Diseases. ,vol. 189, pp. 2167- 2173 ,(2004) , 10.1086/420833
Punnee Pitisuttithum, Peter Gilbert, Marc Gurwith, William Heyward, Michael Martin, Fritz van Griensven, Dale Hu, Jordan W. Tappero, Kachit Choopanya, , Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand The Journal of Infectious Diseases. ,vol. 194, pp. 1661- 1671 ,(2006) , 10.1086/508748
Regina Hofmann-Lehmann, Ryan K. Swenerton, Vladimir Liska, Christian M. Leutenegger, Hans Lutz, Harold M. McClure, Ruth M. Ruprecht, Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Research and Human Retroviruses. ,vol. 16, pp. 1247- 1257 ,(2000) , 10.1089/08892220050117014
, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of Infectious Diseases. ,vol. 191, pp. 654- 665 ,(2005) , 10.1086/428404